Survival Outcomes Among Patients With High-Grade Glioma Treated With 5-Aminolevulinic Acid–Guided Surgery: A Systematic Review and Meta-Analysis

@inproceedings{Gandhi2019SurvivalOA,
  title={Survival Outcomes Among Patients With High-Grade Glioma Treated With 5-Aminolevulinic Acid–Guided Surgery: A Systematic Review and Meta-Analysis},
  author={Sirin Gandhi and Ali Tayebi Meybodi and Evgenii Belykh and Claudio Cavallo and Xiaochun Zhao and Masood Pasha Syed and Leandro Borba Moreira and Michael Lawton and Peter Nakaji and Mark C. Preul},
  booktitle={Front. Oncol.},
  year={2019}
}
Background: High-grade glioma (HGG) is associated with a dismal prognosis despite significant advances in adjuvant therapies, including chemotherapy, immunotherapy, and radiotherapy. Extent of resection continues to be the most important independent prognosticator of survival. This underlines the significance of increasing gross total resection (GTR) rates by using adjunctive intraoperative modalities to maximize resection with minimal neurological morbidity. 5-aminolevulinic acid (5-ALA) is… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 83 REFERENCES

5-ALA and FDA approval for glioma surgery

  • Journal of Neuro-Oncology
  • 2019
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO).

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2018
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL